Feline plasma cell pododermatitis is a rare inflammatory dermatosis, accounting for less than 1.5% of dermatological consultations. It is characterized by soft, purplish swelling of the pads—commonly referred to as "pillow foot"—caused by a massive infiltration of mature plasma cells into the dermis. This mysterious condition can occur at any age but primarily manifests between 4 and 7 years of age, with no clear breed predisposition or sex predilection.

La pododermatite plasmocytaire féline est une dermatose inflammatoire rare qui touche moins de 1,5% des consultations dermatologiques. Elle se caractérise par un gonflement mou et violacé des coussinets, surnommé "pillow foot" en anglais, dû à une infiltration massive de plasmocytes matures dans le derme. Cette affection mystérieuse peut survenir à tout âge mais se manifeste surtout entre 4 et 7 ans, sans prédisposition raciale claire ni distinction de sexe.

The French Bulldog exhibits exceptional dermatological vulnerability, resulting from the complex interaction between its anatomical conformation and specific genetic factors1. Its brachycephalic morphology leads to the formation of deep skin folds, creating a warm, humid microclimate favorable to maceration and intertrigo.... Concurrently, a defective skin barrier, marked by a deficiency in filaggrin and ceramides as well as mutations in the PROM1 and SLAMF1 genes, weakens the epidermis against allergens....

This vulnerability allows for the frequent expression of atopic dermatitis, affecting up to 20% of the breed, often from a young age10.... The disease is characterized by intense inflammation mediated by interleukin-31 and chronic cutaneous dysbiosis. Bacterial superinfections (notably with Staphylococcus pseudintermedius organized in biofilms) and fungal infections (Malassezia) are almost systematic, as is the predisposition to juvenile demodicosis linked to an immune defect....

Therapeutic management requires a strict multimodal strategy. It prioritizes the cytological diagnosis of infectious complications, the restoration of the skin barrier, and the control of pruritus through advanced therapies, such as JAK inhibitors or monoclonal antibodies, aiming to sustainably stabilize this precarious cutaneous balance